Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Non-Hodgkin lymphoma epidemiology and demographics

Introduction

Overview

Overview

In 2015, the incidence of non-Hodgkin lymphoma was estimated to be 24 cases per 100,000 individuals in the United States. In the United States, the age-adjusted prevalence of non-Hodgkin lymphoma is 131.1 per 100,000 individuals in 2011.

Epidemiology and Demographics

Epidemiology and Demographics

  • Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy in the world.[1]
  • NHL ranks as the 7th most common cancer among males and the 6th most common cancer among females.[1]

Incidence

  • The incidence/prevalence of non Hodgkin lymphoma is approximately 13.2 per 100,000 individuals worldwide.[1][2]

Mortality rate

  • Non Hodgkin lymphoma is the 6th most common cause of cancer related death in the world.[1]

Age

Race

  • Non Hodgkin lymphoma usually affects individuals of the Caucasian race.[4]
  • In the US, the relative risk (RR) of HIV-associated NHL in African-American is half that of Caucasians (RR 22.3, 95% CI, 17.1–29 vs. RR 46.2, 95% CI, 38.8–55) mainly due to ethnic variations in immune system regulatory genes.[5]

Gender

  • Men are more commonly affected by non Hodgkin lymphoma than women. The Male to female ratio is approximately 1.5:1 to 3:1.[6][7][8]

Region

  • The majority of non Hodgkin lymphoma cases are reported in North America, Africa and East Asia.[9]
References

References

  1. ↑ 1.0 1.1 1.2 1.3 Anderson JR, Armitage JO, Weisenburger DD (1998). “Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project”. Ann Oncol. 9 (7): 717–20. PMID 9739436.
  2. ↑ Fisher SG, Fisher RI (2004). “The epidemiology of non-Hodgkin’s lymphoma”. Oncogene. 23 (38): 6524–34. doi:10.1038/sj.onc.1207843. PMID 15322522.
  3. ↑ Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S; et al. (2008). “Etiologic heterogeneity among non-Hodgkin lymphoma subtypes”. Blood. 112 (13): 5150–60. doi:10.1182/blood-2008-01-133587. PMC 2597610. PMID 18796628.
  4. ↑ Müller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005). “Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology”. Ann Hematol. 84 (1): 1–12. doi:10.1007/s00277-004-0939-7. PMID 15480663.
  5. ↑ Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O (2011). “Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin’s lymphoma in veterans from the United States”. J Clin Oncol. 29 (4): 378–85. doi:10.1200/JCO.2010.30.1515. PMC 3058284. PMID 21172877.
  6. ↑ Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006). “Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001”. Blood. 107 (1): 265–76. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
  7. ↑ Roman E, Smith AG (2011). “Epidemiology of lymphomas”. Histopathology. 58 (1): 4–14. doi:10.1111/j.1365-2559.2010.03696.x. PMID 21261679.
  8. ↑ Ansell P, Simpson J, Lightfoot T, Smith A, Kane E, Howell D; et al. (2011). “Non-Hodgkin lymphoma and autoimmunity: does gender matter?”. Int J Cancer. 129 (2): 460–6. doi:10.1002/ijc.25680. PMID 20853323.
  9. ↑ Swerdlow S, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. 4. Lyon; 2008. p. 439.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]